drugset
drugset / Trial / NCT07209813

GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma

NCT07209813 ↗

Phase 2 Not yet recruiting 48 enrolled Beijing Gene Key Life Technology Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase II, open-label, randomized, multicenter study to evaluate the efficacy and safety of GKL-006 combine with TACE in adult patients with unresectable Hepatocellular carcinoma.

Timeline

Start
2025-10-12
Primary completion
2026-10-31
Completion
2026-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject iNKT cells Cell therapy 3e+08 unknown Intravenous

Indications

hepatocellular carcinoma